Celebrex may curb colon cancer, but with caveats

People who took a newer type of pain pill over a three-year period were less likely to develop polyps that could lead to colorectal cancer - but at the expense of a higher risk of heart problems, new study findings report.

And when participants stopped taking the pain pill Celebrex (celecoxib) out of concerns over side effects, they eventually developed more polyps than people who had remained on an inactive, or placebo, drug throughout the study.

So should people concerned about their risk of colorectal cancer consider Celebrex?

“The findings in this study don’t necessarily make that decision any easier,” said Dr. Andrew Chan of Massachusetts General Hospital and Harvard Medical School, who did not participate in the research.

The study, published in the American Journal of Gastroenterology, received financial support from Pfizer, which sells Celebrex.

This is not the first study to suggest Celebrex and similar drugs - known as COX-2 inhibitors - may reduce the risk of developing colon cancer, he said, but people need to balance that potential benefit with the higher risk of cardiovascular complications.

As a result, he said he suspects most people would choose to rely on regular colonoscopies to catch the disease in its early stages, rather than take a potentially risky drug for years.

But to people who have no underlying cardiovascular problems and a particularly high risk of colon cancer - they were diagnosed with it before perhaps, or have a strong family history - regular screening may not be enough, Chan noted.

“So for those patients, they might consider taking a drug like this,” he said.

Colorectal cancer is the third most common cancer in men and women, and strikes 1.2 million people each year.

Other research has provided signs that COX-2 inhibitors, which block the COX-2 enzyme that causes inflammation, could also prevent colorectal cancer, as well as lung cancer in heavy smokers.

Page 1 of 21 2 Next »

Provided by ArmMed Media